Silo Pharma Q2 2024 Earnings Report $0.94 -0.02 (-2.15%) (As of 11:51 AM ET) Earnings History Silo Pharma EPS ResultsActual EPS-$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASilo Pharma Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASilo Pharma Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call ResourcesSILO Earnings History The Key to Feeding 8.1 Billion People (Ad)Imagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's food supply. Right now, an under-the-radar company just debuted on the New York Stock Exchange with an IPO and it's currently priced under $15...Get the full name of this company by clicking here. Silo Pharma Earnings HeadlinesSilo Pharma (NASDAQ:SILO) Shareholders Approve Key Proposals at Annual MeetingDecember 22, 2024 | americanbankingnews.comSilo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and FibromyalgiaDecember 18, 2024 | globenewswire.comThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's food supply. Right now, an under-the-radar company just debuted on the New York Stock Exchange with an IPO and it's currently priced under $15...December 26, 2024 | i2i Marketing Group, LLC (Ad)Silo Pharma partners with Kymanox to develop ketamine implantDecember 3, 2024 | msn.comSILO Pharma (NASDAQ:SILO) Stock, Insider Trading ActivityDecember 1, 2024 | benzinga.comSilo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain ManagementNovember 29, 2024 | globenewswire.comSee More Silo Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email. Email Address About Silo PharmaSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma (NASDAQ:SILO) in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.View Silo Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
